Zacks Research Upgrades GeneDx (NASDAQ:WGS) to Strong-Buy

GeneDx (NASDAQ:WGS – Get Free Report) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.

Other equities analysts also recently issued reports about the company. BTIG Research reiterated a “buy” rating and issued a $85.00 target price (down from $90.00) on shares of GeneDx in a research report on Tuesday, November 10th. Wall Street Zen upgraded GeneDx from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research report on Monday, November 2nd. Guggenheim boosted their target price on shares of GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, Canaccord Genuity Group upped their target price on GeneDx from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $90.14.

Read Our Latest Analysis on WGS

GeneDx Trading Down 7.3%

WGS opened at $47.29 on Monday. GeneDx has a twelve month low of $32.21 and a twelve month high of $170.87. The company has a 50-day simple moving average of $72.36 and a 200 day simple moving average of $69.72. The company has a quick ratio of 3.85, a current ratio of 4.16 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -12.51 and a beta of 2.00.

GeneDx (NASDAQ:WGS – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.21. The company had revenue of $123.10 million for the quarter, compared to analyst estimates of $122.93 million. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. During the same quarter last year, the company posted ($0.27) EPS. Analysts predict that GeneDx will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at GeneDx

In related news, CFO Kevin Feeley sold 3,728 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares of the company’s stock, valued at $4,387,081.45. This represents a 7.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the completion of the sale, the chief executive officer owned 115,476 shares of the company’s stock, valued at $11,271,612.36. The trade was a 8.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 19,206 shares of company stock valued at $1,808,056 in the last quarter. 25.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GeneDx

Several institutional investors have recently made changes to their positions in the stock. Cim LLC boosted its holdings in GeneDx by 5.4% in the third quarter. Cim LLC now owns 5,225 shares of the company’s stock worth $378,000 after acquiring an additional 270 shares in the last quarter. Virtu Financial LLC acquired a new stake in GeneDx in the third quarter valued at approximately $1,746,000. Jump Financial LLC bought a new stake in shares of GeneDx during the third quarter valued at approximately $4,134,000. First Trust Advisors LP bought a new stake in shares of GeneDx during the third quarter valued at approximately $2,192,000. Finally, William Blair Investment Management LLC increased its holdings in shares of GeneDx by 11.4% during the third quarter. William Blair Investment Management LLC now owns 1,560,247 shares of the company’s stock valued at $112,806,000 after acquiring an additional 159,594 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

(Get Free Report)

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

See Also

Analyst Recommendations for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.